ArticleBreast cancer research : BCR2017

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.

Nusayba Bagegni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.